AstraZeneca

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

CEO

Pascal Soriot

CEOPascal Soriot

Employees

94,300

Employees94,300

Headquarters

Cambridge, Cambridgeshire

HeadquartersCambridge, Cambridgeshire

Founded

1992

Founded1992

Employees

94,300

Employees94,300

AZN Key Statistics

Market cap

241.88B

Market cap241.88B

Price-Earnings ratio

34.19

Price-Earnings ratio34.19

Dividend yield

1.96%

Dividend yield1.96%

Average volume

6.17M

Average volume6.17M

High today

$77.69

High today$77.69

Low today

$76.74

Low today$76.74

Open price

$76.87

Open price$76.87

Volume

4.92M

Volume4.92M

52 Week high

$87.68

52 Week high$87.68

52 Week low

$62.75

52 Week low$62.75

AZN News

Seeking Alpha 2h

AstraZeneca to buy EsoBiotec to advance cell therapy ambition

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN), it said on Monday. The EsoBiotec Engineered NanoBody Lentivira...

TipRanks 2h

AstraZeneca’s Eneboparatide Shows Promise in Phase III Trial for Hypoparathyroidism

The latest update is out from AstraZeneca ( (GB:AZN) ). AstraZeneca announced that its investigational drug eneboparatide met the primary endpoint in the Phase...

TipRanks 3d

Cellectis SA: Strategic Collaborations and Clinical Advancements Drive Buy Rating

Silvan Tuerkcan, an analyst from JMP Securities, maintained the Buy rating on Cellectis SA (CLLS – Research Report). The associated price target is $6.00. Silv...

Analyst ratings

85%

of 33 ratings

Buy

84.8%

Hold

15.2%

Sell

More AZN News

TipRanks 7d

AstraZeneca’s Promising Pipeline and Market Potential Drive Buy Rating Amid Positive Competitor Data

Morgan Stanley analyst Sarita Kapila has maintained their bullish stance on AZN stock, giving a Buy rating today. Sarita Kapila has given her Buy rating due to...